Stockwinners Market Radar for June 27, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

12:55 EDT Arogo Capital Acquisition Corp trading halted, news pending

12:45 EDT Denali Capital Acquisition Corp trading resumes

12:30 EDT Denali Capital Acquisition Corp trading halted, volatility trading pause

12:02 EDT Uber unveils One Less Car trial, offers $1,000 to drivers to use other transport - Uber announced the One Less Car trial, a new 5-week challenge where up to 175 selected participants across the U.S. and Canada will give up their personal car and instead use alternate forms of transportation, like walking, public transit, cycling, and rideshare. The company said that car owners in Los Angeles, Chicago, Washington D.C., Miami, San Francisco, Toronto, and Vancouver can participate int he program from July 22 to August 25. Based on the average monthly cost of vehicle ownership in the U.S., the company provide selected participants with $1,000 to use alternative transportation options to get around instead of relying on their private car. These options will include car-free offerings like public transit, Lime e-bikes and e-scooters bookable in the Uber app, plus car rentals, and rideshare. "We've partnered with the Behavioural Insights Team, a research consultancy specializing in behavioral science, to measure the impacts," Uber added. "Participants will be asked to document their experience throughout the trial, taking note of what transportation alternatives they use and the impact embracing a car-light lifestyle makes on their everyday experiences." Reference Link

12:00 EDT Onity Group rises 10.5% - Onity Group is up 10.5%, or $2.35 to $24.83.

12:00 EDT SM Energy falls -11.3% - SM Energy is down -11.3%, or -$5.46 to $42.95.

12:00 EDT Elanco falls -22.0% - Elanco is down -22.0%, or -$3.96 to $14.02.

15:44 EDT Xbox Game Pass members can play games on Amazon Fire TV devices via cloud - Microsoft's (MSFT) Xbox announced a collaboration with Amazon (AMZN) where Xbox Game Pass Ultimate members in over 25 countries can play games directly from the Xbox app on select Fire TV devices via cloud gaming, giving people even more choice in how they play their favorite games. In July, the Xbox app will be available on the Fire TV Stick 4K Max and Fire TV Stick 4K. To get started, players just need a Fire TV Stick, a Bluetooth-enabled wireless controller, and an Xbox Game Pass Ultimate membership to gain instant access to hundreds of phenomenal games, including "Senua's Saga: Hellblade II," "Starfield," and "Forza Horizon 5," among others. Reference Link

11:21 EDT Cardio Diagnostic's Epi+Gen CHD test available at Meijer Supercenter - Cardio Diagnostics Holdings announced that the Company's clinical blood test, Epi+Gen CHD is now available at Family Medicine Specialists' retail clinical location at the Meijer Supercenter in McHenry, Illinois.

10:51 EDT Advocacy groups urge government to end VeriSign domain contract - The American Economic Liberties Project announced that it and a "coalition of allies" yesterday sent two separate letters to the National Telecommunications and Information Administration and Department of Justice, respectively, urging them to end VeriSign's "government-designated monopoly over domain registration" before an August 2 deadline to stop the automatic renewal of VeriSign's "no-bid contract." VeriSign's "monopoly is responsible for rising costs of the most coveted website domains," the agency said in a statement. Shares of VeriSign are down 87c to $178.23 in morning trading. Reference Link

10:44 EDT MicroAlgo Inc trading halted, volatility trading pause

10:35 EDT Blue Lion issues letter to HomeStreet board of directors - Blue Lion Capital, a Dallas-based investment firm that beneficially owns approximately 1.3% of the stock of HomeStreet, has issued a letter to the HomeStreet Board of Directors regarding Change in Control payments that the company's management team may receive as part of the FirstSun Capital Bancorp merger. Blue Lion learned that at the time of the original merger announcement on January 16th of this year that FSUN management strongly encouraged HomeStreet's CEO Mark Mason to hedge the interest rate risk imbedded in the fixed rate loan and securities portfolios that caused HMST all the problems to begin with. Mark Mason refused. Over the ensuing months, interest rates increased and the value of the two portfolios declined. Based on the 8k released last week, HMST shareholders voted against the CIC payments to be made to Mark Mason and other named executive officers. However, the outcome of the vote was "advisory and non-binding." Griege stated "Shareholders have spoken and the Board needs to do its fiduciary duty and follow the wishes of shareholders." Griege goes on to say, "Candidly, this outcome was not surprising with the poor performance of the stock and the Board over the past twelve years. Shareholders have been fleeced by this management team and Board." Blue Lion encourages shareholders to contact James Mitchell, HomeStreet's Lead Independent Director to strongly discourage any CIC payments being made to HMST's management team.

10:15 EDT Fitell Corp trading resumes

10:01 EDT Skeena Resources rises 8.4% - Skeena Resources is up 8.4%, or 36c to $4.64.

10:01 EDT Suzano rises 11.8% - Suzano is up 11.8%, or $1.08 to $10.29.

10:01 EDT Levi Strauss falls -16.2% - Levi Strauss is down -16.2%, or -$3.74 to $19.38.

09:55 EDT Boeing sanctioned by NTSB for sharing non-public information with media - The National Transportation Safety Board announced a series of restrictions and sanctions on Boeing after the company blatantly violated NTSB investigative regulations-and Boeing's signed party agreement with the NTSB-by providing non-public investigative information to the media and speculating about possible causes of the Jan. 5 door-plug blowout on a Boeing passenger jet in Portland, Oregon. During a media briefing Tuesday about quality improvements at Boeing Commercial Airplanes, a Boeing executive provided investigative information and gave an analysis of factual information previously released. Both of these actions are prohibited by the party agreement that Boeing signed when it was offered party status by the NTSB at the start of the investigation. As a party to many NTSB investigations over the past decades, few entities know the rules better than Boeing. Because of Boeing's recent actions, Boeing will retain its party status, but no longer have access to the investigative information the NTSB produces as it develops the factual record of the accident. The NTSB may subpoena any relevant records it requires during the course of the investigation. The NTSB will also subpoena the company to appear at an investigative hearing into the case scheduled for Aug. 6 and 7 in Washington, DC. Unlike the other parties in the hearing, Boeing will not be allowed to ask questions of other participants. Given that Boeing is under investigation by the U.S. Department of Justice in relation to its Deferred Prosecution Agreement stemming from Boeing's interactions with the FAA prior to the Boeing MAX fatalities, the NTSB will be coordinating with the DOJ Fraud Division to provide details about Boeing's recent unauthorized investigative information releases in the 737 MAX 9 door plug investigation. Reference Link

09:50 EDT GRDI Stock trading resumes

09:48 EDT Skeena Resources rises 6.5% - Skeena Resources is up 6.5%, or 28c to $4.56.

09:48 EDT Elanco falls -10.9% - Elanco is down -10.9%, or -$1.95 to $16.02.

09:47 EDT Levi Strauss falls -15.6% - Levi Strauss is down -15.6%, or -$3.60 to $19.52.

09:40 EDT Singular Genomics Systems trading resumes

13:33 EDT Nevada reports May gaming win up 2.45% to $1.32B - Nevada's Gaming Control Board also reported May Las Vegas Strip gaming win up 3.71% to $745.49M. Publicly traded companies in the gambling space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (FLUT), Gan Limited (GAN), Genius Sports (GENI), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn Entertainment (PENN), Rush Street Interactive (RSI), Sportradar (SRAD) and Wynn Resorts (WYNN).

09:32 EDT Lanvin Group appoints Peter Copping as artistic director - Lanvin Group announced that Lanvin has appointed Peter Copping as Artistic Director. He will take the role as the creative lead for womenswear and menswear collections, starting from September 2024. Most recently, Copping served as Head of Couture at Balenciaga where he directed the ateliers for the reintroduction of the couture collection.

09:28 EDT AbbVie acquires Celsius Therapeutics for $250M in cash - AbbVie announced the acquisition of Celsius Therapeutics, a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius' lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibody that has completed a Phase 1 clinical study for the treatment of IBD. Under the terms of the agreement, AbbVie has acquired all outstanding Celsius equity for $250M in cash, subject to certain customary adjustments.

09:20 EDT GT Biopharma announces FDA clearance of IND application for GTB-3650 - GT Biopharma announced FDA clearance of its IND application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to start in second half of 2024. The Phase 1 dose escalation study will evaluate GTB-3650 in up to six cohorts of adult patients with relapsed or refractory CD33 expressing hematologic malignancies, including acute myeloid leukemia and high-risk myelodysplastic syndrome. GTB-3650 will be dosed in two-week blocks, two weeks on and two weeks off for up to four months based on clinical benefit. The trial will assess safety, pharmacokinetics, pharmacodynamics, in vivo expansion of endogenous patient NK cells and clinical activity.

09:17 EDT Serve Robotics expands delivery service in Los Angeles - Serve Robotics announced the expansion of its delivery operations into Koreatown as part of a long-term plan to broaden its geographic reach in Los Angeles and across the U.S. Additionally, in preparation for the scale up of its fleet for future expansions, Serve announced the expansion of its lidar supply agreement with Ouster to equip its next-generation robots with upgraded sensors for enhanced performance. In June, Serve began onboarding local merchants in partnership with Uber Eats. As part of the expanded lidar supply agreement, Serve Robotics will continue to outfit its fleet with digital lidar, using Ouster's new REV7 sensors.

09:14 EDT PacBio, FormBio collaborate to launch resources for AAV design, analysis - Form Bio and PacBio announced a range of new initiatives aimed at advancing and unifying the AAV industry. The initiatives, including an AAV data dictionary, open-source tools and more, are being driven by a new AAV Working Group, jointly assembled by Form Bio and PacBio and composed of leading AAV experts across industry and academia. The resulting materials are being made available on a new AAV Resource Hub at aav.formbio.com. AAV is widely recognized as one of the most promising technologies for gene therapy due to its non-pathogenic nature. However, collaboration on AAV-based programs is often hindered by industry silos that lead to divergent terminology and methods, which can differ widely between various companies and institutions operating at the forefront of AAV innovation. In addition, the lack of standard definitions and practices works against uniformity of regulatory submissions, making it harder and more time consuming for regulatory agencies to evaluate potential new therapies. In response, Form Bio and PacBio have convened leading experts to form an AAV Working Group dedicated to developing and promoting standardized nomenclature and reporting practices to foster consistency and reliability in AAV research and development. The charter of the newly formed AAV Working Group is to develop standardized nomenclature, establish standardized reporting, and promote widespread adoption of these initiatives.

09:11 EDT Varonis achieves FedRAMP 'In Process' designation - Varonis Systems announced it has secured the "In Process" designation with the Federal Risk and Authorization Management Program, FedRAMP. This designation affirms that Varonis aligns with the goals to promote secure and compliant cloud services to the federal government. Michael Wallace, President, U.S. Public Sector, Varonis, said, "Varonis is proud to partner with federal agencies to support their mission. Achieving the FedRAMP "In Process" designation restates our commitment to being a vendor of choice in securing critical data for federal entities, and makes it easier for federal teams to turn to Varonis' cloud-native solution to reduce their blast radius, monitor and respond to threats, and prevent data breaches."

09:11 EDT Elanco delays expected Credelio Quattro approval to Q4 - The company said this morning, "For Credelio Quattro, two of three major technical sections - Effectiveness and Safety - are complete, however, in June, the Company received an incomplete letter for the CMC major technical section. Elanco has already submitted its response to the two questions in the letter, which did not require any additional data generation. The FDA has offered a shortened, 60-day review timeline for Elanco's response. Following this, the minor technical section reviews will be completed, including Labeling. The product is then expected to go through the 60-day final administrative review, placing the expected approval in the fourth quarter of 2024, with U.S. launch expected in the first quarter of 2025." The company previously guided to a launch in the second half of 2024. Shares of Elanco are down 8% to $17.97 in premarket trading.

09:10 EDT Freddie Mac to launch Multifamily Giant PCs - Freddie Mac announced the company will soon launch a new product offering, Multifamily Giant Participation Certificates, which are single-class pass-through securities collateralized by existing Freddie Mac Multi PCs and/or Multifamily Giant PCs.

09:08 EDT Elanco expects boxed warning for Zenrelia, sees slower adoption - The company said this morning, "Elanco continues to view Zenrelia as positively differentiated for effectiveness and convenience, which we believe can address unmet needs in the market. However, we expect the U.S. label will include a boxed warning on safety based on the outcome of a trial with unvaccinated dogs dosed at 3x the label dose. While we remain confident in Zenrelia's blockbuster potential, we believe this warning will slow the product adoption curve in the U.S. and initially limit the number of expected treatment days by approximately 25%. We plan to conduct additional research to support an improved label over time." Shares of Elanco are down 8% to $17.97 in premarket trading.

13:07 EDT NexGel subsidiary announces it will supply SilverSteal to Cintas - NEXGE (NXGL) announced it will supply SilverSeal to Cintas (CTAS), a leading provider of corporate identity uniforms, first aid and safety products, and services to over 1 million businesses across North America. Through this supply arrangement, Cintas will distribute SilverSeal to its customers in many sectors such as hospitality and public service. The first order of SilverSeal is expected to be delivered during the fourth quarter of 2024. Adam Levy, CEO of NEXGEL, commented, "This partnership with one of the nation's leading providers of products and services for businesses across the U.S. is significant to us not only for the associated revenue, but also for SilverSeal's brand awareness. We are proud that SilverSeal has been selected by Cintas as a solution for their customers."

09:06 EDT GRI Bio announces KIPO granted patent for NKT cell modulators - GRI Bio announced that the Korean Intellectual Property Office, KIPO, has granted Patent No. 10-2665487 titled, "Prevention and Treatment of Inflammatory Conditions." The granted patent covers claims including compositions and methods for modulating type 2 and/or type 1 invariant NKT, iNKT, cells in the prevention and treatment of inflammatory conditions. More specifically, the patent covers the prevention and treatment of inflammatory, fibrotic and autoimmune conditions through the administration of a Retinoic Acid Receptor, RAR, agonist that inhibits iNKT cells in a subject.

09:05 EDT CleanSpark to acquire Griid Infrastructure for $155M - CleanSpark (CLSK) and Griid Infrastructure (GRDI) have entered into a definitive merger agreement pursuant to which CleanSpark will acquire all the issued and outstanding common stock of Griid in an all-stock transaction. The total enterprise value of the transaction is $155M. Concurrent with the signing of the merger agreement, the companies also entered into an exclusive hosting agreement for all currently available power, of which 20 MW will be allocated to CleanSpark effective immediately. CleanSpark will assume all outstanding debt and other obligations of Griid pursuant to the merger. CleanSpark also provided Griid with a $5M dollar working capital loan and a pay-down bridge loan of approximately $50.9M that was used to satisfy certain obligations of GRIID at signing. The loan is secured and is senior to all other outstanding debt of Griid. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in Q3. The acquisition is subject to Griid shareholder approval and other customary closing conditions.

09:04 EDT Matterport, FBS partner to introduce listing-completion feature - Matterport announced its partnership with FBS. FBS represents more than 320,000+ real estate professionals across the US and offers a comprehensive real estate technology platform that includes the Flexmls system. Flexmls is a powerful MLS platform designed to provide real estate professionals with access to property listings, market data, and tools for managing their business. A fully mobile MLS system, the Flexmls Platform gives real estate professionals the autonomy to run their business on their terms. This partnership enables Flexmls users to easily upload their Matterport digital twins, and autofill dimensional data from those twins directly into the Flexmls platform with just one click. Flexmls users will also gain efficiency through the seamless upload of Matterport media, including photos, floor plans, and videos.

09:02 EDT Matson raises quarterly dividend to 34c from 32c per share - The Board of Directors of Matson has declared a third quarter dividend of 34c per common share. The dividend represents a 2c, or 6.3%, increase over the previous quarter's dividend and will be paid on September 5 to all shareholders of record as of the close of business on August 1.

08:55 EDT Hims & Hers now down 15% to $18.36 following Hunterbrook report

08:53 EDT Gan Limited receives CFIUS clearance for Sega Sammy merger - Gan Limited announced that it has received clearance from the Committee on Foreign Investment in the United States, or CFIUS, for the proposed merger of Gan and a subsidiary of Sega Sammy Creation, or SSC, an affiliate of Sega Sammy. The closing of the merger is also subject to approval of the merger and change in control of Gan by certain gaming authorities. The closing of the merger remains subject to other customary closing conditions, and is expected to occur in late 2024 or early 2025. If the merger is completed, each GAN ordinary share issued immediately prior to the effective time of the merger will be automatically cancelled and converted into the right to receive $1.97 in cash with respect to each such ordinary share, without interest and less applicable withholding taxes. Upon the completion of the merger, Gan will cease to be a publicly traded company and its ordinary shares will be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended.

08:48 EDT ARIA Cybersecurity Solutions partners with Forescout Technologies - ARIA Cybersecurity Solutions announced a new integration partnership with Forescout Technologies. Forescout helps customers detect, protect, and respond to the latest risks and threats. With a deep view of asset intelligence captured throughout the Forescout Platform, customers have better visibility of active risks and threats, enabling them to make better risk prioritization and mitigation decisions. ARIA's AZT PROTECT zero trust solution provides a lock-down approach to protecting critical production applications from attack, with a focus on stopping all forms of malware, ransomware as well as nation-state backed attacks on these applications and the OS on which they run. ARIA is working with Forescout to integrate AZT PROTECT into the Forescout Platform to provide the ultimate in critical application visibility, protection and zero trust enforcement.

08:45 EDT CMC Metals acquires 80% interest in Blue Heaven Property - MC Metals announced that the Company has completed the final payment on the Blue Heaven Property with the optionor Strategic Metals and as a result is now an 80% owner of the Property. The original final payment of the option agreement was amended and subsequently a payment of 5,000,000 common shares at a deemed price of $0.03 per share, with a four month hold period, was provided to Strategic as the final payment for the Property. The Blue Heaven Property comprises of 118 claims that are contiguous to the Company's Silver Hart Project in south-central Yukon. Blue Heaven is characterized with 13 mineralized areas and 36 showings many of which are yet to be evaluated by the Company. A brief program in 2022 extended previous trenching at the Desire Showing with highly positive results including: 8.0 meters grading 13.39% lead, 1.57% zinc, 359.25 g/t silver and 1.17% manganese including 1.0 meter of 10% lead, 5.1% zinc, 1,500 g/t silver and 2.3% manganese; 13.0 meters grading 8.25% lead, 4.22% zinc, 151.57 g/t silver and 9.16% manganese including 1.0 meter of 23.86% lead, 0.9% zinc, 623 g/t silver and 2.3% manganese; A 14.0 meter mineralized area including 1.0 meter samples containing: 3.61% lead, 3.1% zinc, 199 g/t silver, 12.6% manganese;10% lead, 2.5% zinc, 360 g/t silver and 3.7% manganese; 10% lead, 8.5% zinc, 459 g/t silver, and 1.6% manganese. Several other 1.0 meter length individual samples containing: 49.8% lead, 3.7% zinc, 857 g/t silver and 5.7% manganese; 13.4% lead, 5.6% zinc, 167 g/t silver and 10.5% manganese; 59.46% lead, 1.8% zinc, 1,076 g/t silver and 3.2% manganese; 21.01% lead, 1.1% zinc, 820 g/t silver and 1.4% manganese; 16.53% lead, 0.3% zinc, 425 g/t silver and 0.7% manganese; 64.56% lead, 5.6% zinc, greater than1,500g/t silver and 2.3% manganese; 29.26% lead, 0.7% zinc, 1,295 g/t silver and 0.5% manganese. These preliminary results demonstrate the potential for stacked manto sequences but require a lot more investigation to be conclusive in this regard. The area around the Golden Cross Zone is also characterized by several outcrops with extensive manganese which has been found to be indicative of silver-lead-zinc CRD-style mineralization on the Silver Hart property. These areas will be further evaluated with trenching and detailed mapping once an exploration permit has been secured for the property. In addition, a bulk sample collected by Nordac Resources Ltd. in 1999 from the Blue and H zones by comprised of 51.47 dry tonnes grading 8,563 g/t silver, 56.2% lead, 9.5% zinc and 1.2 g/t gold. Also, a recent in-depth analysis completed by Ronacher-McKenzie Geosciences on the 2021 SkyTEM airborne electromagnetic survey identified four areas of exploration prospectivity that were deemed to merit detailed evaluation. A permit application including a renewal for exploration at Silver Hart and proposed exploration activities at Blue Heaven has been submitted and accepted for review by the Yukon Environmental and Assessment Board.

08:43 EDT Bridgeline Digital's AI-powered HawkSearch selected by calendar retailer - Bridgeline Digital announced a large calendar retailer has chosen Bridgeline's HawkSearch to power product discovery for its eCommerce website. HawkSearch will enhance the retailers' revenue through its AI-powered search bar that offers a more personalized user experience. The calendar retailer will use HawkSearch to increase sales using features such as Smart Search and Recommendations. The improved website can utilize Smart Search to provide the customer with the product they are looking for in a far more personalized and accurate way. Ari Kahn, CEO of Bridgeline, stated, "Our partnership with the calendar retailer showcases our dedication to supporting revenue growth for eCommerce retailers. HawkSearch's AI-powered search capabilities are a necessity for creating easy to navigate online shopping experiences that drive sales."

08:40 EDT Global Technologies increases shareholder equity via preferred stock exchange - Global Technologies has entered into a Share Exchange Agreement to increase the Company's shareholder equity. On June 25, 2024, the Company filed a designation for a new series of preferred stock, titled Series N Preferred Stock, with the Secretary of State of the State of Delaware. The Holders of the Series N shall vote together with the outstanding shares of Class A Common Stock and have a fixed conversion price of $.50 per share. On June 26, 2024, the Company entered into a Share Exchange Agreement with each of the Holders of the Company's Series L Preferred Stock. As of the date of the Agreement, there were a total of 339 shares of Series L outstanding. As per the terms of the Agreement, shares of Series L were exchanged for shares of the newly designated Series N. A total of 1,864,500 shares of Series N were issued. All outstanding shares of Series L were retired. The exchange of outstanding Series L shares for Series N shares increases the Company's shareholder equity by approximately $1.8 million.

08:39 EDT CytoDyn announces start of preclinical MASH study - CytoDyn announced that its preclinical MASH study with SMC Laboratories has commenced, with results expected in the fall of 2024. CytoDyn believes its prior MASH study demonstrated a statistically significant benefit of leronlimab at a dosing level of 350 mg. To clarify the optimal dosing and evaluate the potential for combination therapy, SMC will be conducting a twelve-week preclinical mouse study evaluating both 350 and 700 mg dose levels, alone and in combination with Resmetirom, a drug recently approved by the FDA. The study will evaluate leronlimab's potential role in preventing and/or reversing liver fibrosis.

08:38 EDT Oragenics develops automated intranasal device for concussed patients - Oragenics announced it has completed a prototype of its automated intranasal device for use in concussed patients who are initially confused, dazed or unconscious in the acute phase of injury. Oragenics' lead drug candidate, ONP-002, is a new chemical entity, NCE, designed to target the brain through delivery into the nasal cavity and onward to the brain. A Phase II study is being designed to analyze the effectiveness of ONP-002 on blood biomarkers and patient-reported outcomes of concussed patients. "We are excited about this new automated technology as it allows us to treat the full range of concussive injuries. Both devices offer advantages and can deliver our nanoparticle powder. Given the early mental alterations many concussed patients experience, we aim to provide them the best drug delivery route to improve their clinical outcomes," stated Michael Redmond, President at Oragenics.

08:36 EDT Intelligent Bio Solutions expands presence in the UK retail sector - Intelligent Bio Solutions announced the expansion of its customer network within the UK retail sector. This includes the adoption of INBS' Intelligent Fingerprinting Drug Screening System by three prominent UK retailers, among the largest and most recognized in the country. The recently secured accounts employ over 55,000 individuals and include a British multinational retailer specializing in clothing, footwear, and accessories, a major UK-based kitchen retailer and manufacturer, and a British retail group specializing in sports and leisure clothing, footwear, and equipment. Two retailers have transitioned from traditional third-party saliva testing to INBS's fingerprint drug screening technology. The switch to a more streamlined, hygienic, and less invasive testing methodology has addressed business and policy alignment issues and previous testing inefficiencies, facilitating smoother processes that enable larger testing volumes.

08:34 EDT ARB IOT Group receives notice of noncompliance from Nasdaq - ARB IOT Group announced that on June 25, 2024, it received a written notification letter from The Nasdaq Stock Market, notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's ordinary shares for the 31 consecutive business days from May 9, 2024 through June 24, 2024, the Company no longer meets the minimum bid price requirement. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of the Notification Letter. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until December 23, 2024 to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the Company's ordinary shares is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance with the minimum bid price requirement by December 23, 2024, the Company may be eligible for an additional 180 calendar day grace period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary, to Nasdaq. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determination to delist the Company's ordinary shares, at which point the Company will have an opportunity to appeal the delisting determination to a Hearings Panel. The Notification Letter has no immediate effect on the listing of the Company's ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker "ARBB"

08:25 EDT Pixelworks announces restructuring plan, 16% workforce reduction - In a regulatory filing, Pixelworks said, "On June 25, 2024, the Board of Directors of Pixelworks approved a restructuring plan to make the operation of the company more efficient and which would result in an approximately 16% reduction in workforce, in the areas of operations, research and development, sales, marketing and administration. The Board and management believe adoption of this restructuring plan will help streamline the company's operations and workforce, and more appropriately align the company's operating expenses with current revenue levels. The company expects the restructuring to be substantially complete by the end of the second quarter ending June 30, 2024 and expects to incur total estimated restructuring charges of approximately $1.7 million related to employee severance and benefits. The company expects that these charges will largely be recorded in the second quarter of 2024. In addition to the restructuring charges, the restructuring plan includes the payment by Pixelworks Semiconductor Technology of $1.2 million collectively to those terminated employees who are holders of an interest in one of the five employee stock ownership entities that were established to enable employee ownership of Pixelworks Shanghai. Per the terms of the ESOP agreements, PWSH must re-purchase from the ESOP such shares that are attributable to the withdrawing former employees for the amount invested plus annual interest of 5%, accrued to the date of withdrawal. Each former employee must withdraw from the ESOP, and the ESOP will remit to them the amounts paid by PWSH. The company expects this process to be completed within the third quarter of 2024. PWSH shall hold the Repurchased Shares as treasury stock, which can be re-issued to new employees in connection with the ESOP equity plan within the next three years, at which point any remaining shares must be cancelled. While held as treasury stock, the Repurchased Shares will not be eligible for voting. The total number of Repurchased Shares will equate to 0.50% of all PWSH shares. As a result of the restructuring, the company expects to realize annualized savings of approximately $4.0 million."

08:21 EDT VSee Health awarded virtual care purchasing agreement with Premier - VSee Health announces a group purchasing agreement for virtual care services with Premier a technology-enabled healthcare improvement company. This new agreement provides Premier members with special pricing and terms for VSee Health's customizable telehealth solutions. Under the agreement, VSee Health will provide its innovative virtual care platform to Premier's network of hospitals and healthcare providers across the U.S. This collaboration aims to enhance patient care, improve clinical outcomes and reduce healthcare costs through efficient and accessible telehealth solutions. VSee Health's platforms offer a comprehensive suite of telehealth services, including video consultations, remote patient monitoring and AI-driven analytics, all designed to support healthcare providers in delivering exceptional patient care remotely. "This new agreement with Premier supports our mission of expanding access to quality healthcare and transforming healthcare delivery. The comprehensive VSee platform is also available a la carte, which gives providers maximum flexibility to embed our solutions into their existing telehealth workflow streams for enhanced patient care," said Milton Chen, Ph.D., Co-CEO of VSee Health.

12:19 EDT Ryde Group partners with Mobile-health Network Solutions in quick commerce - Ryde Group (RYDE) announced a partnership with Mobile-health Network Solutions (MNDR). Ryde and MaNaDr signed a definitive partnership agreement to further collaboration in the telehealth and quick commerce space.This collaboration aims to enhance the well-being of Ryde's driver-partners and their families by providing them with greater access to affordable healthcare services. It underscores our commitment for the driver-partners and their families to benefit from convenient telemedicine consultations, making healthcare readily available even while on the road. By allowing quick consultations for common illnesses or injuries, it minimizes downtime and maximizes earning potential, addressing a major concern for driver-partners.

08:18 EDT Sezzle announces Payment Streaks feature now available to Canadian users - Sezzle announces that its Payment Streaks feature is now available to Canadian users. "Following its successful launch among U.S. consumers, we are excited to bring this feature to Canada, rewarding Sezzle users for consistently making timely payments, promoting financial responsibility and enhancing the overall customer experience," the company said.

08:15 EDT Xylo Technologies announces Charging Robotics secures first commercial order - Xylo Technologies announces that Charging Robotics, held 67% by Xylo, received its first commercial order for the deployment of its wireless charging system designed for automatic parking facilities. This order comes from Parking Design. This collaboration marks an important progress in the evolution of automated parking and electric vehicle charging technologies. The purchase order is for a first batch of 12 systems, capable of wireless charging. This innovation ensures that several EVs can be charged at the same time, significantly improving the efficiency and convenience of automatic parking facilities. The order is scheduled to be fulfilled throughout 2025, ensuring that the systems are fully operational and integrated into Parking Design's facilities within the year.

08:14 EDT Tourmaline Bio promotes Robinson to Chief Financial Officer - Tourmaline Bio announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, effective June 25, 2024. Robinson most recently held the role of Vice President, Finance and Controller at Tourmaline, in addition to serving as Tourmaline's Interim Chief Financial Officer and Treasurer since October 2023.

08:12 EDT HUB Security announces $15M refinancing, capital raise - HUB Cyber Security restructured $8 million of its debt that was due this month. In addition, Hub Security has secured an additional $2 million in debt financing. Key shareholders have also exercised warrants at an exercise price of $0.90 per share, resulting in an additional $5 million in capital.

08:11 EDT Kratos Defense announces launch, flight of Kratos Erinyes Hypersonic Test Bed - Kratos Defense & Security Solutions announced that its Space & Missile Defense Systems Business Unit, a part of Kratos' Defense & Rocket Support Systems Division, supported the Missile Defense Agency and the Naval Surface Warfare Center, in the successful launch and flight of the Kratos Erinyes Hypersonic Test Bed, on June 12, 2024, from the NASA Wallops Flight Facility in Virginia. This first flight of the Erinyes vehicle demonstrates a new and novel platform capability for rapid hypersonic experimentation for the U.S. Department of Defense. The exercise, designated Hypersonic Test Bed-1, demonstrated hypersonic flight that enabled the collection of data for multiple experiments to be provided to test teams for design validation and evaluation of new technologies.

08:09 EDT Annovis Bio files provisional patent for manufacturing process of buntanetap - Annovis Bio announced the filing of a provisional patent covering the manufacturing process of new solid forms of buntanetap. This patent encompasses the methods for manufacturing the new crystalline form of buntanetap, which has demonstrated exceptional stability and efficacy. The patent also covers the entire synthesis process, from basic starting materials to finished GMP product, suitable for manufacturing scale at ton quantities. The new process offers significant benefits, including excellent yields, the avoidance of potentially genotoxic reagents, and a purer product. The CMC protocol was submitted to the FDA and will be discussed in July, with the goal of continuing development of our drug and filing the NDA with the new crystal form.

12:08 EDT ViaSat to provide broadband SATCOM for Airbus' C295 fleet in Spain - Viasat (VSAT) is expanding its work with Airbus (EADSY) Defence and Space to provide its secure, flexible broadband Ku- and Ka-band airborne technology for the Airbus C295 Maritime Patrol Aircraft that have been acquired by the Spanish Ministry of Defence. Viasat and Airbus Defence and Space will collaborate on the integration of Viasat's dual-band broadband terminal into the Spanish C295 MPA fleet to provide SATCOM capability to support missions utilizing the SpainSat NG satellites.

08:07 EDT Rezolute announces exercise of underwriters' option to purchase shares - Rezolute announced that the underwriters of its previously announced public offering, which closed on June 24, 2024, have exercised an over-allotment option to purchase an additional 1,786,589 shares of the Company's common stock at the public offering price of $4.00 per share, less underwriting discounts and commissions. After giving effect to the option closing, the total number of shares sold by the Company in the offering were 13,036,589 shares, which along with pre-funded warrants to purchase up to an aggregate of 3,750,000 shares of its voting common stock, resulted in aggregate gross proceeds to the Company of approximately $67 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In addition, the Company has entered into an agreement for a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended, of 1,500,000 shares of its common stock, at a sale price of $4.00 per share. Jefferies and Cantor served as the joint book-running managers for the public offering. BTIG, Craig-Hallum, H.C. Wainwright & Co., Jones and Maxim Group LLC are acting as co-managers for the public offering.

08:06 EDT Tilray announces activations, events, launches to celebrate Fourth of July - Tilray Brands announced an array of exciting activations, events, and product launches to celebrate this Fourth of July with its renowned craft beer and beverage brands-Breckenridge Brewery, SweetWater, 10 Barrel Brewing, and Montauk Brewing and newly launched Runner's High. The brands are gearing up for a spectacular holiday with a series of unique events and experiences for all. This upcoming long weekend, those brands are turning up the heat on seasonal celebrations with a delectable offer that will delight grill masters and beer lovers alike. As summer heats up, so does the opportunity to indulge in one of America's favorite pastimes: a good old-fashioned barbecue. To enhance these summer gatherings, get $3 back when you buy your favorite beer from Shock Top, SweetWater Brewing, 10 Barrel Brewing, Montauk Brewing, or Blue Point Brewing, along with your favorite hot dogs and veggie dogs.

08:05 EDT CalciMedica's Auxora shows efficacy in Acute Pancreatitis Phase 2b trial - CalciMedica announced positive topline data from CARPO, the company's Phase 2b trial evaluating Auxora for the treatment of acute pancreatitis with accompanying systemic inflammatory response syndrome. The trial established a dose response for Auxora across multiple endpoints, identified both the target patient population and the likely drug dose for a pivotal trial, and re-affirmed Auxora's safety profile and tolerability as seen in prior clinical trials. CARPO met its study objective by showing a dose response for time to solid food tolerance as well as other clinical endpoints. The primary endpoint of median time to solid food tolerance in the pre-specified subgroup of patients with hyper-inflammatory acute pancreatitis showed a statistically significant dose response with placebo patients requiring 4.7 days to tolerate solid food and patients in the high dose group showing a 1.9 day improvement vs. placebo, the medium dose group a 2.1 day improvement and the low dose group a 1.5 day improvement. In patients without hyper-inflammatory AP, Auxora did not show a measurable benefit. Additionally, Auxora demonstrated a statistically significant dose response in reduction of severe organ failure. Auxora was well-tolerated. There were no deaths in the high dose or low dose group. CalciMedica intends to present additional data from CARPO at a medical meeting later this year.

08:04 EDT Allarity granted hearing before Nasdaq to present plan of regaining compliance - Allarity Therapeutics announced that it received notice from the NASDAQ Stock Market that it was granted a hearing before a Nasdaq Hearings Panel. This upcoming hearing, occurring in approximately 5 weeks, is scheduled for the Company to present its plan for regaining compliance following Nasdaq's notification, disclosed in Allarity's Form 8-K filed with the SEC on June 21, 2024, of Allarity's non-compliance with Nasdaq Listing Rule 5550(a)(2), also known as the Bid-Price Rule. This rule requires that a company's stock maintain a minimum bid price of $1.00 per share for at least 30 consecutive business days.

08:03 EDT BranchOut Food announces retailer increases store count, sales of contract - BranchOut Food announced that the nation's largest retailer has increased the store count and overall projected sales of its third contract with BranchOut Food. The new third contract now has a value of approximately $1 million in sales and is three times larger than the retailer's original projection. The retailer will offer the private label products in 3,430 stores across the nation, up from an original store count of 1,400. "We are excited about the rapid pace of adoption and popularity of BranchOut Food's products, and very pleased to be increasing our private label offering with this large, brand-name retailer," said Eric Healy, CEO of BranchOut Food. "Private label products are a key segment of our business, and we are actively pursuing opportunities for growth in this segment."

08:02 EDT Dare Bioscience announces 1-for-12 reverse stock split - Dare Bioscience announced that it will implement a 1-for-12 reverse split of the issued shares of its common stock, effective on July 1, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Monday, July 1, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol "DARE." The reverse stock split is intended to increase the bid price of the common stock to enable the Company to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.

08:01 EDT New York Community Bancorp approves one-for-three reverse stock split - New York Community Bancorp announced that as previously approved by its shareholders at its annual meeting held on June 5th, its Board of Directors passed a resolution yesterday approving the one-for-three reverse stock split. We expect the reverse stock split to become effective in mid-to-late July.

07:57 EDT Syra Health awarded contract with Missouri Department of Mental Health - Syra Health has secured a contract with the Missouri Department of Mental Health to provide qualified behavioral health professionals for various locations throughout the state. This is Syra Health's second active contract in the state of Missouri.

07:50 EDT NextSource Materials announces global anode expansion strategy update - NextSource Materials announced an update on its global anode expansion strategy, including positive results of a technical and economic study for the construction of a proposed battery anode facility located in the Kingdom of Saudi Arabia. The Company further announces it has launched a strategic partner process to consider expressions of interest it has received for funding the battery anode facilities both in the Middle East and globally. As announced in February 2023, NextSource plans to construct, in stages, multiple BAFs globally in key jurisdictions that would be capable of producing commercial scale graphite anode active material for lithium-ion batteries used in electric vehicle applications. This planned series of BAFs will leverage exclusive access to well-established proprietary anode processing technology currently supplying anode active material to major EV automotive companies. The key jurisdictions being evaluated for potential BAF expansions are Madagascar, the KSA, the United Arab Emirates, and North America. Anode active material comprises a range of value-added graphite products including spheronized purified graphite and coated SPG.

07:48 EDT Purple Biotech reports interim results from Phase 2 Pancreatic Cancer study - Purple Biotech reported additional interim data from its randomized, controlled, open label, multicenter Phase 2 study of CM24, in combination with Bristol Myers Squibb's immune checkpoint inhibitor nivolumab and standard of care chemotherapy, in second-line metastatic pancreatic ductal adenocarcinoma. These results suggest that serum MPO may be a predictive biomarker for survival in the CM24+Nivolumab + Nal-IRI/5FU/LV arm. The company also announced that it will host a virtual KOL event on Thursday, July 11, 2024 at 10:30 AM ET to discuss the results in detail. Interim results that were presented on June 1, 2024 during a late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting demonstrated a 26% reduction in risk of death and a 28% risk reduction in progression or death in previously-treated patients treated with CM24+nivolumab+Nal-IRI/5FU/LV vs. Nal-IRI/5FU/LV chemotherapy alone. Median OS was prolonged by 2.1 months and median PFS was extended by 1.9 months in the CM24+nivolumab+Nal-IRI/5FU/LV regimen vs. SoC. The prolongation of both OS and PFS by the CM-24-nivolumab therapy is further supported by a higher ORR, DCR, and decrease in CA19-9 level. New Interim Exploratory Biomarker Data: This interim biomarker analysis comparing the experimental and control arms suggests measured baseline serum MPO as a potential clinical outcome biomarker for CM24-nivolumab therapy. Enhanced MPO levels were measured in greater than90% of the patients with mean MPO over 6-fold higher than healthy donors. The mean MPO is used as a threshold for evaluating MPO as a potential biomarker.The effect of the CM24-nivolumab therapy in combination with Nal-IRI/5FU/LV is most pronounced among patients with serum MPO levels below the mean MPO and is associated with OS improvement of 3.6 months in median OS of 8.1 months vs. 4.5 months. While in a small sample size, these findings suggest that serum MPO may be a predictive biomarker for the treatment effect of CM24+Nivo+ Nal-IRI/5FU/LV on OS. Presentation of the biomarker data is planned at an upcoming medical conference. The experimental arms of the randomized Phase 2 study administered patients with CM24 plus nivolumab and a choice of one of two SoC chemotherapies used in second-line PDAC, and dependent on prior first line therapy regimen; either gemcitabine/nab-paclitaxel or liposomal irinotecan/5-fluorouracil and leucovorin, while the control arms administered either respective SoC chemotherapy alone. Interim results are provided for the Nal-IRI/5FU/LV sub study. An analysis of the gemcitabine/nab-paclitaxel sub study will be performed later when the data sufficiently matured. CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein responsible for tumor immune evasion and poor tumor response and/or resistance to immune checkpoint inhibitors. Neutrophil extracellular traps which are involved in immune evasion and metastasis known to affect disease progression and patient survival. CM24, a CEACAM1 antibody, was reported1 to also bind to NET structures and significantly suppresses the NET-induced migration of various cancer cells, as an additional Mechanism of Action. In an earlier part of this study, CM24+nivolumab treatment significantly reduced the level of the NET marker, as represented by measurable MPO in patient serum.

07:42 EDT BioRestorative Therapies announces notice of allowance for ThermoStem patent - BioRestorative Therapies has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-564135 related to the Company's allogeneic, off-the-shelf ThermoStem platform. Previously published peer-reviewed preclinical data from a study conducted in collaboration with the University of Utah School of Medicine demonstrated a clonogenic population of metabolically active brown adipose tissue stem cells residing in adult humans that: can be expanded in vitro; exhibit multilineage differentiation potential; and, functionally differentiate into metabolically active brown adipocytes. In addition, the preclinical results confirmed that multipotent brown adipose derived stem cells induced to differentiate into brown adipocytes exhibit the mature functional properties of these cells, including increased mitochondrial activity, an important functional characteristic of BAT. In the UUSOM study, data obtained in high-fat fed NOD-SCID mice transplanted with differentiated BADSCs supported by a BioRestorative-developed 3D Porous Extracellular Matrix-Derived Scaffold showed significant reductions in weight, triglyceride and blood glucose levels compared to saline-only injected controls. The study also demonstrated that BioRestorative's 3D scaffold was capable of retaining viable transplanted cells for at least five weeks post-implantation. This, the fifth Japanese patent to issue for BioRestorative's ThermoStem technology platform, covers a method of making three-dimensional brown adipose derived stem cell aggregates in the absence of differentiation medium.

07:35 EDT FSD Pharma receives HREC approval for Phase 1 MAD trial of LUCID-21-302 - FSD Pharma has received approval by the human ethics review committee in Australia for its trial entitled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants." Lucid-21-302 is a non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis. It is a patented New Chemical Entity that has been shown in preclinical models to prevent demyelination, a known cause of MS and other neurogenerative diseases characterized by damage to the myelin sheath surrounding nerve fibers in the central nervous system. In addition, the company issued 400,000 Class B Subordinate Voting shares in the capital of the Corporation to arm's length creditors at the deemed price of $0.30 per Class B Share to settle an aggregate of $120,000 of amounts owing.

07:34 EDT Cronos Group's Spinach brand expands portfolio with new summer launches - Cronos Group's Spinach brand is expanding its portfolio of cannabis products. Summer innovations feature new flavors and formats from Cronos' SOURZ by Spinach edibles and a premier milled flower product.

07:32 EDT Venus Concept announces completion of NEXThetics events - Venus Concept announced the completion of its NEXThetics events held across several major cities in North America. NEXThetics events bring together Venus Concept's network of aesthetic leaders and practitioners and have seen a significant increase in popularity and attendance. Since our pilot events, the Company has hosted thousands of registrants, including its largest gathering to date in Houston, Texas on June 22, 2024. "NEXThetics Houston was an outstanding event, centering on the core principles of the latest technology, networking, and delivering an unparalleled experience among attendees," says Dr. Cheryl Haseeb of Pura Medical Aesthetics in Houston, Texas. "The attendees were highly engaged and eager to learn about the science behind this cutting-edge brand. They left energized and inspired to take their practice to the next level. It's truly inspiring to witness the positive impact this event has had on our professional community." Looking ahead to the remainder of 2024, NEXThetics Events will continue to expand across the United States, with upcoming events in Phoenix, Las Vegas, New York City, Atlanta, Dallas and Minneapolis.

07:31 EDT Cheche Technology enters partnership with Beijing Anpeng - Cheche Group announced that it has entered into a strategic partnership with Beijing Anpeng Insurance Broker Co., Ltd., as Cheche continues to deepen its collaborations with new energy vehicle manufacturers in China. Beijing Anpeng is a subsidiary of Beijing Automotive Group Co., Ltd. and specifically handles the insurance business of BAIC Group's car brands. BAIC Group is one of the largest auto manufacturers in China, producing and selling vehicles through its own brands as well as foreign-branded joint-ventures. These brands include ARCFOX, Beijing Automotive, Beijing Hyundai, Beijing Benz and Beijing Off-road, among others. The partnership names Cheche as the core partner of BAIC Group to provide digital insurance solutions for its various brands.

07:29 EDT Walgreens Boots Alliance sees headwinds persisting into FY25 - Comments taken from Q3 earnings conference call presentation slides.

07:23 EDT Natera announces single-arm adjuvant trial in gastroesophageal cancer - Natera announced a new gastroesophageal cancer trial, DECIPHER, that will utilize the company's personalized and tumor-informed molecular residual disease MRD test, Signatera , to guide patient selection and assess the rate of MRD clearance in patients being treated for gastroesophageal cancer. DECIPHER is a single-arm, open-label phase II trial, and the first trial to evaluate the efficacy of a HER2-directed antibody-drug conjugate in gastroesophageal adenocarcinoma EGC patients in the adjuvant setting. The study plans to enroll 25 patients from more than 10 sites across the United Kingdom. Patients who are Signatera-positive following neoadjuvant chemotherapy and surgery will forgo standard-of-care adjuvant chemotherapy and receive the investigational therapy for a maximum of eight cycles. Signatera will be used to measure MRD-positivity following surgery and serially thereafter, with MRD clearance serving as the primary endpoint. "With an adaptive approach aimed at eliminating MRD, DECIPHER is designed to offer patients a second chance at a cure when they have not responded to standard of care therapies," said Dr. Elizabeth Smyth, M.D., consultant in medical oncology at Oxford University Hospitals NHS Foundation Trust l and chief investigator of the trial. "Signatera's personalized, tumor-informed approach, which has demonstrated high sensitivity across several different cancer types including EGC, will be a key component of this study."

11:21 EDT NOG announces accretive Uinta Basin joint acquisition with SM Energy - Northern Oil and Gas ( NOG) announced that it has entered into a definitive agreement to acquire a 20% undivided stake in the XCL Assets in partnership with SM Energy (SM) for a purchase price, net to NOG, of $510.0 million in cash, subject to customary closing adjustments. The Acquired Assets are located primarily in Uintah and Duchesne Counties, Utah and include approximately 9,300 net acres and 97.6 underwritten net undeveloped locations, normalized for 10,000 foot laterals. Significant additional upside locations remain in the Deep and Upper Cube. The prospective development plan is based on conservative and widened spacing from the current operator. The Company sees substantial return upside from increased lateral lengths (extending to 3-miles) and cost savings from an integrated co-owned sand mine facility scheduled to come online within twelve months. Upon closing and transition of services, the operator of substantially all of the assets will be SM, with NOG participating in development pursuant to cooperation and joint development agreements entered into in connection with the acquisition. "The Uinta Basin has emerged as one of the best and fastest growing oil resources in the United States, and SM has a track record as one of our best and most responsible operators. We look forward to working with them for many years to come. We believe this transaction will be the most accretive in our history, benefiting per share net profit and free cash flow both immediately and over time." "With XCL, we are acquiring a multi-stacked pay acreage position with significant long-term upside," commented Adam Dirlam, NOG's President. "These assets are exemplary of our returns-focused strategy: delivering immediately while offering significant exploration potential further enhancing NOG's optionality. Much like our prior joint development transactions, we have devised an aligned, conservative development and governance plan with a proven E&P company. We continue to be the partner of choice for our operators as the largest, best capitalized and most reliable working interest owner in the United States."

07:18 EDT ADC Therapeutics set to join Russell 2000, Russell 3000 Indexes - ADC Therapeutics announced that the Company is set to join the Russell 2000 Index and the broad-market Russell 3000 Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024.

11:17 EDT SM Energy says Northern to buy 20% of oil & gas assets of XCL for $510M - Northern Oil and Gas, will acquire an undivided twenty percent (20%) of the oil and gas assets of XCL for $510 million, resulting in a $2.04 billion purchase price net to the Company for an undivided 80% interest of the assets . SM Energy intends to serve as the operator of the assets currently operated by XCL. The Company plans to finance the acquisition through a combination of debt and cash on hand.

07:14 EDT Gilat Satellite receives over $14M in orders expanding into IFC market - Satellite Networks announced that it has secured over $14M in orders from several prominent service providers and system integrators for its In-Flight Connectivity, IFC, products and solutions. These include Network equipment, Solid State Power Amplifiers, SSPAs, and additional IFC auxiliary products. These orders demonstrate the company's leadership position in the growing IFC market for commercial and business aviation. This position will be significantly strengthened with Gilat's recent acquisition of Stellar Blu Solutions. Gilat's airborne solutions, renowned for their superior performance, reliability, and user experience, are deployed globally and on thousands of IFC enabled aircraft.

07:13 EDT Xtract One selected by NHL's Panthers to secure entrances to Amerant Bank Arena - Xtract One Technologies announced its SmartGateway has been selected to protect all entrances at Amerant Bank Arena, Baptist Health IcePlex, and FTL War Memorial by the Florida Panthers of the National Hockey League, NHL. SmartGateways will be deployed over the course of the next year at all entrances to increase security at upcoming events at these venues.

07:12 EDT Radware introduces enhanced API Protection solution - Radware has enhanced its API Protection solution with a new AI-driven, auto-learning protection engine designed to immediately detect and mitigate business logic attacks. Working in real-time, the engine exposes bad actors' identities and automatically detects and blocks malicious API calls by continuously learning the application's business logic. The solution offers organizations comprehensive coverage for the OWASP API 2023.

11:10 EDT SM Energy to acquire oil & gas assets of XCL Resources for $2.55B - SM Energy announces that it has entered into an agreement to acquire the Uinta Basin oil and gas assets owned by certain entities affiliated with XCL Resources , a private company backed by EnCap Investments and Rice Investment Group for an unadjusted purchase price of $2.55B. Concurrently, Northern Oil and Gas, Inc. ( NOG) will acquire an undivided twenty percent (20%) of the oil and gas assets of XCL for $510 million, resulting in a $2.04 billion purchase price net to the Company for an undivided 80% interest of the assets . SM Energy intends to serve as the operator of the assets currently operated by XCL. The Company plans to finance the acquisition through a combination of debt and cash on hand...This value-driven acquisition meets SM Energy's strategic objectives: Expected to be immediately accretive to key metrics: Acquired for 2.9x NTM Adjusted EBITDAX( the acquisition is expected to be immediately accretive to key financial metrics. Based on 2025E projections, 2025E Adjusted EBITDAX is expected to increase ~35%, 2025E Adjusted free cash flow is expected to increase ~45%, and 2025E cash production margin(6) is expected to increase ~11%.

07:10 EDT Clearside Biomedical to host KOL event on July 24 - Clearside Biomedical announced plans to host a virtual key opinion leader, KOL, event on Wednesday, July 24, 2024. The event will highlight the broad applicability and real-world experience with suprachoroidal drug delivery, the SCS as a differentiator in the retinal treatment landscape with a focus on neovascular age-related macular degeneration, and ongoing SCS clinical programs, including potential future development opportunities for Clearside.

07:09 EDT Lantheus acquires global rights to Life Molecular Imaging's GRPR - Lantheus Holding announced its acquisition of the global rights of Life Molecular Imaging's RM2, targeting the gastrin-releasing peptide receptor, GRPR, including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair, referred to as 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2. This acquisition strengthens Lantheus' presence in prostate cancer and expands its pipeline to include breast and other cancers. The agreement includes global rights1 to this radiotheranostic pair for an upfront payment of $35 million and potential regulatory milestone payments plus royalties. "While new PSMA-targeted diagnostics and therapeutics are transforming prostate cancer care, there are many patients for whom PSMA-targeted therapy may not be appropriate," said Brian Markison, Lantheus CEO. "Targeting GRPR with 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 creates a potential new option to expand access to radiotheranostics for more prostate cancer patients. This expands our therapeutic offerings and opens avenues for commercial synergies."

07:09 EDT Walgreens Boots Alliance provides update on strategic review - The company is finalizing significant multiyear footprint optimization program to close certain underperforming U.S. stores; launching U.S. Retail Pharmacy action plan to invest in and deliver an improved customer and patient experience across channels; aligning U.S. Pharmacy and Healthcare organizations for enhanced go-to-market capabilities and simplifying and focusing the U.S. Healthcare portfolio.

07:06 EDT Lantronix launches EDS5000 Series Device Server - Lantronix announced the launch of its new next-generation desktop or 1U rack mountable EDS5000 series of device servers, supporting 8, 16 or 32 serial managed devices over Ethernet for easy remote access and management of any serial-based equipment, such as medical devices, POS terminals or security equipment.

07:04 EDT Monte Rosa provides development progress updates on MRT-2359, MRT-6160 - Monte Rosa Therapeutics announced progress updates for its two lead programs, MRT-2359, an MGD being developed for MYC-driven solid tumors, and MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases. Monte Rosa continues to evaluate MRT-2359 in a Phase 1/2 clinical trial in MYC-driven solid tumors. The Company has completed enrollment of the 0.5 mg, 21 days on, 7 days off dose escalation cohort, and tolerability has been favorable with an AE profile similar to what has been observed using the 5 days on, 9 days off schedule at the same dose level. Enrollment is ongoing in the 0.75 mg, 21 days on, 7 days off dose escalation cohort. The Company is evaluating possible Phase 2 expansion cohorts, and anticipates utilizing a two-stage design to enroll patients to evaluate responses in each selected expansion cohort before proceeding with further enrollment. The final determination of recommended Phase 2 dose and updated clinical results anticipated in H2 2024. MRT-6160 is on track for initiation of a Phase 1 SAD/MAD study this summer with Phase 1 clinical data expected in Q1 2025. Monte Rosa expects to subsequently initiate proof-of-concept studies in autoimmune/inflammatory diseases including ulcerative colitis and rheumatoid arthritis, with additional potential POC studies in dermatology, rheumatology, and neurology indications.

07:03 EDT Palantir and Voyager Space partner to leverage AI in space technology sector - Palantir Technologies entered a strategic partnership with Voyager Space, a global space exploration company. Together, Voyager and Palantir aim to advance the space and defense technology sectors by integrating Palantir's AI tools across the Voyager enterprise. Voyager will leverage Palantir Foundry and the Artificial Intelligence Platform to drive value in its in-house payload management system for International Space Station customers, as well as onboard the Starlab commercial space station in the future. It is also building a prototype "Customer Hub" for its customers to submit payload requests via Palantir's software.

07:02 EDT Optinose announces XHANCE added to Express Scripts' national formularies - Optinose announced that XHANCE has been added to Express Scripts' national formularies, including the National Preferred, Flex, and Basic formularies, among the largest commercial formularies in the U.S. with more than 24 million lives. "XHANCE is approved for treatment of chronic rhinosinusitis and, importantly, is the only medication approved for by far the most common type - without nasal polyps, so we are very pleased that Express Scripts has added XHANCE as a preferred option to these formularies," said Ramy Mahmoud, MD, MPH, CEO of Optinose. "We look forward to seeing the addition of XHANCE to these Express Scripts national formularies result in increased patient access to the only evidence-based prescription treatment for this disease."

06:51 EDT Grifols falls 7% after Moody's downgrades credit rating - Shares of Grifols are moving lower after Moody's yesterday downgraded the company's credit rating to B3f from B2. "We expect Grifols' liquidity to be adequate in the next 12 months, but beyond that the maintenance of an adequate liquidity will be premised on Grifols' return to positive FCF generation, which has not yet materialized," Moody's said in its report. Shares of Grifols are down 7% to $6.50 in premarket trading.

06:36 EDT KalVista begins trial for sebetralstat in children with hereditary angioedema - KalVista Pharmaceuticals initiated the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema, or HAE. The trial will enroll approximately 24 children aged 2 to 11 years across seven countries. If approved, sebetralstat would be the first oral on-demand therapy in pediatric patients aged 2 - 11 years, and only the second FDA-approved on-demand therapy of any type in this population.

06:34 EDT X4 Pharmaceuticals' mavorixafor shows efficacy in chronic neutropenia - X4 Pharmaceuticals announced positive new clinical data from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of mavorixafor, an oral CXCR4 antagonist, in the treatment of people with chronic neutropenia. An interim analysis of data from the ongoing six-month study showed that once-daily oral mavorixafor was generally well tolerated and durably increased participants' absolute neutrophil counts both as a monotherapy and in combination with stable doses of injectable granulocyte colony-stimulating factor, the only therapy approved in the U.S. for severe chronic neutropenia. Findings from the interim analysis show: 100% of 6 evaluable participants who had completed the six-month study achieved target ANC increase at Months 3 and 6 on once-daily mavorixafor therapy with or without stable-dose G-CSF; participants on mavorixafor monotherapy achieved mean ANC levels above the lower limit of normal for CN at Month 3 and Month 6; mavorixafor monotherapy also durably increased ANC in participants with severe CN; participants on mavorixafor in combination with stable-dose G-CSF experienced increases in mean ANC of greater than1,000 cells/microL.

06:31 EDT Elanco updates expected FDA approval timelines for Zenrelia, Credlio Quattro - Elanco announced updates to the expected FDA approval timelines for Zenrelia and Credelio Quattro. For Zenrelia, the company has received confirmation from FDA that all major technical sections are complete as of late June. For the Labeling minor technical section, earlier this week the company aligned with FDA on the language and expects to receive the completion letter by mid-July. The 60-day final administrative review will follow, placing expected approval late in the third quarter of 2024. The company now anticipates a U.S. launch for Zenrelia in the fourth quarter of 2024. Zenrelia has also received its first approval in Brazil by the Brazilian Minister of Agriculture, Livestock and Food Supply, with launch planned for the fourth quarter of 2024. Additional reviews are ongoing in other markets, including Canada, Europe and Japan. For Credelio Quattro, two of three major technical sections - Effectiveness and Safety - are complete, however, in June, the Company received an incomplete letter for the CMC major technical section. Elanco has already submitted its response to the two questions in the letter, which did not require any additional data generation. The FDA has offered a shortened, 60-day review timeline for Elanco's response. Following this, the minor technical section reviews will be completed, including Labeling. The product is then expected to go through the 60-day final administrative review, placing the expected approval in the fourth quarter of 2024, with U.S. launch expected in the first quarter of 2025. The company continues to expect positive differentiation related to effectiveness.

06:05 EDT RH Chairman & CEO Gary Friedman purchases $10M of RH stock - RH announced that Chairman & CEO Gary Friedman completed the purchase of $10M of RH stock at an average price per share of $216.10 representing 46,274 shares. With this purchase, Friedman beneficially owns as of June 26, 2024, 5,051,337 shares, or 25.1% of the outstanding shares of RH common stock, based on 18,445,222 shares outstanding as of June 7, 2024, as reported in RH's first quarter fiscal 2024 Form 10-Q. This represents an increase in Friedman's beneficial ownership by 0.2%.

10:03 EDT Global Net Lease sells Americold Portfolio for $170M - Global Net Lease (GNL) announced the successful disposition of a portfolio of nine cold storage properties that are currently leased to subsidiaries of Americold Realty Trust (COLD) for $170M, at a 7.88% cash cap rate on 3.3 years of weighted average remaining lease-term. This disposition is a significant achievement in GNL's ongoing strategic disposition initiative and aligns with the company's 2024 full-year guidance, which projected a disposition cash cap rate range of 7% to 8%. GNL plans to use the net proceeds from this sale to reduce outstanding debt and further lower the company's leverage. The sale of this portfolio, which GNL acquired for $153.4M, is part of the previously announced $567M of closed and pipeline dispositions at a cash cap rate of 7.2%.

05:33 EDT JPMorgan comments on Federal Reserve 2024 stress test - JPMorgan Chase has reviewed the Federal Reserve's 2024 stress test results and specifically the Federal Reserve's projections for Other Comprehensive Income, or OCI. Based on the Firm's own assessment, the benefit in OCI appears to be too large. Should the Firm's analysis be correct, the resulting stress losses would be modestly higher than those disclosed by the Federal Reserve. As of March 31, the firm reported a standardized common equity tier 1, or CET1, capital ratio of 15%, as compared with current regulatory requirements of 11.9%, which represents approximately $54B of excess capital.

05:27 EDT Nokia to sell ASN to the French State - Nokia entered into an agreement with the French State regarding the sale of submarine networks business ASN. Nokia has signed a put option agreement with the French State contemplating the sale of ASN for an Enterprise Value of EUR 350M, subject to informing and consulting with relevant employee representative bodies. Nokia announced it has entered into a put option to sell Alcatel Submarine Networks, or ASN, a submarine networks business, to the French State, represented by the Agence des participations de l'Etat, or APE, subject to informing and consulting with the relevant employee representatives at ASN and Nokia. Nokia will retain a 20% shareholding with board representation to ensure a transition until targeted exit, at which point the French State would acquire Nokia's remaining interest. By divesting ASN, a non-core standalone business for Nokia, Nokia can focus its Network Infrastructure portfolio on growth opportunities in its core markets. Beginning with the second quarter, Nokia expects to account for ASN as a discontinued operation. Going forward, Nokia's Network Infrastructure Business Group will comprise three units: Fixed Networks, IP Networks and Optical Networks. This is expected to reduce the net sales of Network Infrastructure by approximately EUR 1B but will increase its operating profit margin by 100 -150 basis points. This does not impact Nokia's previously stated financial outlook disclosed in its Q1 financial report. The proposed sale of ASN to the French State is the result of discussions which concluded that the French State is the most relevant custodian of ASN. The sale is expected to close at the end of 2024 or beginning of 2025, subject to formal consultation of ASN's French Works Council and other customary closing conditions and regulatory approvals.

05:18 EDT SharkNinja announces AKI as exclusive distribution partner in UAE - Al Khayyat Investments, or AKI, has been appointed as the exclusive distribution partner in the UAE for SharkNinja. SharkNinja products will now be available locally for the first time in the Middle East beginning in the UAE. Shark and Ninja products will now be available across the UAE through its partnership with AKI Consumer Goods, which has been a go-to-market partner and growth engine for global brands in the Middle East.

05:06 EDT Cnooc Enping 21-4 Oilfield Development Project commences production - Cnooc announced that Enping 21-4 Oilfield Development Project has commenced production. The project is located in eastern South China Sea, with an average water depth of approximately 89 meters. It will be developed by leveraging the existing production facilities and is expected to achieve a peak production of approximately 5,300 barrels of oil equivalent per day in 2025. The oil property is light crude. The company endeavors to improve project efficiency through technological and managerial innovation. Enping 21-4 oilfield was developed with two extra extended reach wells drilled from the existing production platform. The well depth exceeds 9,500 meters. The successful application of the development mode has set an example for similar projects of the company. Cnooc holds 100% interest in this project and acts as the operator.